DLT, responses, and outcome
| Patient no. . | Dose of Len, mg/d . | DLT . | Hematologic response . | OR* . | No. of cycles . | Relapse progression . | Death . |
|---|---|---|---|---|---|---|---|
| 101 | 5 | − | PR | + (H,L,K) | 9 | − | − |
| 102 | 5 | − | Stable | − | 7 | − | − |
| 103 | 5 | − | PR | − | 9 | + | − |
| 204 | 10 | − | No | − | 1 | + | + |
| 205 | 10 | − | PR | + (K) | 6 | − | + |
| 206 | 10 | − | CR | + (K) | 9 | − | − |
| 207 | 10 | − | Stable | − | 6 | + | − |
| 308 | 15 | − | CR | + (K) | 9 | − | − |
| 309 | 15 | − | PR | + (H) | 9 | − | − |
| 310 | 15 | − | No | − | 2 | + | + |
| 311 | 15 | − | Stable | − | 2 | + | − |
| 312 | 15 | − | PR | − | 4 | + | − |
| 314 | 15 | − | PR | + (H,K) | 8 | − | − |
| 315 | 15 | − | No | − | 2 | + | + |
| 316 | 15 | − | Stable | − | 3 | + | − |
| 317 | 15 | − | CR | + (K) | 9 | − | − |
| 318 | 15 | − | CR | + (K,L) | 9 | − | − |
| 319 | 15 | − | CR | + (H,K) | 9 | − | − |
| 320 | 15 | − | CR | + (L) | 9 | − | − |
| 421 | 20 | − | No | − | 2 | + | + |
| 422 | 20 | − | PR | + (H,K) | 9 | − | − |
| 423 | 20 | Grade 4 anemia | No | − | 2 | + | − |
| 424 | 20 | Grade 4 neutropenia, 10 days | PR | + (K) | 8 | − | − |
| 425 | 20 | Grade 3 cerebrovascular ischemia | Stable | − | 1 | − | − |
| 426 | 20 | Grade 3 muscle pain | No | − | 4 | + | − |
| 427 | 20 | − | PR | + (H,K) | 9 | − | − |
| Patient no. . | Dose of Len, mg/d . | DLT . | Hematologic response . | OR* . | No. of cycles . | Relapse progression . | Death . |
|---|---|---|---|---|---|---|---|
| 101 | 5 | − | PR | + (H,L,K) | 9 | − | − |
| 102 | 5 | − | Stable | − | 7 | − | − |
| 103 | 5 | − | PR | − | 9 | + | − |
| 204 | 10 | − | No | − | 1 | + | + |
| 205 | 10 | − | PR | + (K) | 6 | − | + |
| 206 | 10 | − | CR | + (K) | 9 | − | − |
| 207 | 10 | − | Stable | − | 6 | + | − |
| 308 | 15 | − | CR | + (K) | 9 | − | − |
| 309 | 15 | − | PR | + (H) | 9 | − | − |
| 310 | 15 | − | No | − | 2 | + | + |
| 311 | 15 | − | Stable | − | 2 | + | − |
| 312 | 15 | − | PR | − | 4 | + | − |
| 314 | 15 | − | PR | + (H,K) | 8 | − | − |
| 315 | 15 | − | No | − | 2 | + | + |
| 316 | 15 | − | Stable | − | 3 | + | − |
| 317 | 15 | − | CR | + (K) | 9 | − | − |
| 318 | 15 | − | CR | + (K,L) | 9 | − | − |
| 319 | 15 | − | CR | + (H,K) | 9 | − | − |
| 320 | 15 | − | CR | + (L) | 9 | − | − |
| 421 | 20 | − | No | − | 2 | + | + |
| 422 | 20 | − | PR | + (H,K) | 9 | − | − |
| 423 | 20 | Grade 4 anemia | No | − | 2 | + | − |
| 424 | 20 | Grade 4 neutropenia, 10 days | PR | + (K) | 8 | − | − |
| 425 | 20 | Grade 3 cerebrovascular ischemia | Stable | − | 1 | − | − |
| 426 | 20 | Grade 3 muscle pain | No | − | 4 | + | − |
| 427 | 20 | − | PR | + (H,K) | 9 | − | − |
Len indicates lenalidomide.
Type of organ response: PR, partial response; H, heart; L, liver; and K, kidney.